INSIGHTS ON DRUG DEVELOPMENT
-
Three Keys To E&L Success: Study Design, Partner Selection, And Timing
Successful E&L planning starts before testing begins. Aligning study design, partner expertise, and timing helps teams focus on the right risks, avoid surprises, and support stronger development.
-
Chemoenzymatic N-glycan Conjugation Of Native mAbs Provides Homogeneous, Efficacious ADCs
A chemoenzymatic two-stage protocol enables DAR2 ADCs from native, non-engineered mAbs via glycan remodeling at Asn-297 and copper-free click chemistry, with in vivo efficacy outperforming a comparable marketed ADC.
-
How Organ-Chips Are Transforming Women's Reproductive Health Research
Traditional models often fall short in women’s health research. Learn how human-relevant Organ-Chip systems are providing new ways to study vaginal, cervical, and uterine biology.
-
Are You Keeping Pace With Oligo Synthesis Optimization?
The rapidly expanding oligo market demands optimized RNA synthesis. Examine key innovations and workflow insights to maximize resources and control long-term manufacturing costs.
-
Generate CHO-K1 GFP-Expressing Cells For Cell Line Development Workflow11/7/2025
Discover a high-efficiency workflow for generating GFP-expressing CHO-K1 clones using automated single-cell dispensing to achieve 93% isolation success and stable expression in under five weeks.
-
Small Molecule Orphan Drugs: Status Quo, Challenges, And Perspectives3/11/2026
By establishing robust manufacturing processes and scalable production strategies from the outset, developers can help de-risk orphan drug production, improve efficiency, and position their programs for greater long-term success.
-
Exosome Production From hMSC Using A Fixed-Bed Bioreactor11/3/2025
Explore a high-yield, scalable process for hMSC-derived exosome production using fixed-bed bioreactors, with strong performance in purity, recovery, and biological activity.
-
CDMOs - Key Collaborators In Streamlining Drug Development12/12/2025
Accelerating biologics development requires more than speed. Discover how the right CDMO partnership can streamline processes and help you reach the market faster without sacrificing control.
-
A Universal Workflow Approach For Single Cell Mass Spectrometry Based Proteomics11/7/2025
Learn about a streamlined workflow that improves reproducibility, reduces contamination, and simplifies single-cell proteomics with comparable results to FACS.
DRUG DEVELOPMENT SOLUTIONS
-
Are you using obsolete or aging instruments simply because they continue to work? Running your laboratory with outdated technology brings about challenges beyond just headaches. Older technology may limit your performance, increase your costs, and open your lab up to risk. It may be time to investigate the real cost of using obsolete technology.
With the Waters FlexUP Technology Renewal Program, always work with the latest technology for optimum productivity and security.
-
As part of Stevanato Group’s commitment to R&D, our analytical testing facilities focus on investigating physico-chemical properties of primary packaging materials and components and studying the interactions between container closure system and drugs. Stevanato Group relies on a multi-disciplinary team of highly skilled professionals, including, scientists, engineers, pharmaceutical chemists and biotechnologists. Their knowledge and experience covers a range of specialized areas including container closure systems and drug-delivery devices.
-
This pipeline outlines a sequence of late‑stage and emerging therapeutics projected to launch between 2024 and 2031, spanning immunology, neurology, psychiatry, rare disease, oncology, and inflammatory disorders.
-
Our integrated approach brings together drug substance, drug product and clinical activities, supporting the expediting of lead molecules from FIH into POC trials.
-
Characterize Samples and Identify Unknown Components
Do you often need to identify unknown compounds from complex samples? ACD/MS Structure ID Suite offers a simple, replicable workflow for generating and narrowing down structural candidates.
- Deconvolute complex LC/MS and GC/MS data into individual component traces
- Search proprietary and commercial databases for spectral matches
- Search PubChem for accurate-mass and molecular-formula matches
- Narrow down candidate structures by retention time and fragment include/exclude lists